Association between omentin-1, bone metabolism markers, and cytokines of the RANKL/RANK/OPG system in girls with anorexia nervosa

Endokrynologia Polska

Volumn 66, Issue 6, 2015, Pages 514-520

  Gobek, Karolina ^a   Ostrowska, Zofia ^a   Ziora, Katarzyna ^a   Owiêcimska, Joanna ^a   Swiêtochowska, Elbieta ^a   Marek, Bogdan ^a   Kajdaniuk, Dariusz ^a   Strzelczyk, Joanna ^a   Kos Kuda, Beata ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Anorexia nervosa; Bone metabolism; Girls; Omentin 1; OPG; SRANKL

Indexed keywords

ALKALINE PHOSPHATASE; CARBOXY TERMINAL TELOPEPTIDE; OMENTIN 1; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROTEIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; UNCLASSIFIED DRUG; COATOMER PROTEIN; CYTOKINE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; ITLN1 PROTEIN, HUMAN; LECTIN; TNFSF11 PROTEIN, HUMAN;

ADOLESCENT; ANOREXIA NERVOSA; ARTICLE; BLOOD SAMPLING; BODY MASS; BONE METABOLISM; BONE REMODELING; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; NUTRITIONAL STATUS; OSSIFICATION; PROTEIN BLOOD LEVEL; WEIGHT REDUCTION; BLOOD; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADOLESCENT; ANOREXIA NERVOSA; BONE REMODELING; COATOMER PROTEIN; CYTOKINES; FEMALE; GPI-LINKED PROTEINS; HUMANS; LECTINS; OSTEOCALCIN; RANK LIGAND;

EID: 84949747002     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: 10.5603/EP.2015.0063     Document Type: Article

References (38)

1. Magni P, Dozio E, Galliera E et al. Molecular aspects of adipocytokine-bone interactions. Curr Mol Med 2010; 10: 522-532.
2. Reid IR. Fat and bone. Arch Biochem Biophys 2010; 503: 20-27.
3. Zaidi M, Buettner C, Sun L et al. Minireview: the link between fat and bone: does mass beget mass? Endocrinology 2012; 153: 2070-2075.
4. Fasshauer M, Blüher M. Adipokines in health and disease. Trends Pharmacol Sci 2015; 36: 461-470.
5. Yang RZ, Lee MJ, Hu H et al. Identifcation of omentin as a novel depot-specifc adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 2006; 290: 1253-1261.
6. Duan XY, Xie PL, Ma YL et al. Omentin inhibits osteoblastic differentiation of calcifying vascular smooth muscle cells through the PI3K/Akt pathway. Amino Acids 2011; 41: 1223-1231.
7. Xie H, Xie PL, Wu XP et al. Ometin-1 attenuates arterial calcifcation and bone loss in osteoprotegerin-defcient mice by inhibition of RANKL expression. Cardiovasc Res 2011; 92: 296-306.
8. Xie H, Xie PL, Luo XH et al. Omentin-1 exerts bone-sparing effect in ovariectomized mice. Osteoporos Int 2012; 23: 1425-1436.
9. Kearns AE, Khosla S, Kosteniuk PJ. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 2008; 29: 155-192.
10. Silva I, Branco JC. RANK/RANKL/OPG: Literature review. Acta Reumatol Port 2011; 36: 209-218.
11. Wang D, Jiang TJ, Liao L et al. Relationships between serum omentin-1 concentration and bone mineral density, and bone biochemical markers in Chinese women. Clin Chim Acta 2013; 426: 64-67.
12. Tohidi M, Akbarzadeh S, Larijani B et al. Omentin-1, visfatin and adiponectin levels in relation to bone mineral density in Iranian post-menopausal women. Bone 2012; 51: 876-881.
13. De Souza Batista CM, Yang RZ, Chen C et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes 2007; 56: 1655-166.
14. Tan BK, Adya R, Farhatullah S et al. Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome: ex vivo and in vitro regulation of omentin-1 by insulin and glucose. Diabetes 2008; 57: 801-808.
15. Moreno-Navarrete JM, Catalan V, Ortega F et al. Circulating omentin concentration increases after weight loss. Nutr Metab (Lond) 2010; 7: 27
16. Catli G, Anik A, Abaci A et al. Low omentin-1 levels are related with clinical and metabolic parameters in obese children. Exp Clin Endocrinol Diabetes 2013; 121: 595-600.
17. Guo LJ, Jiang TJ, Liao L et al. Relationship between serum omentin-1 level and bone mineral density in girls with anorexia nervosa. J Endo-crinol Invest 2013; 36: 190-194.
18. Jaikanth C, Gurumurthy P, Cherian KM et al. Emergence of omentin as a pleiotropic adipocytokines. Exp Clin Endocrinol Diabetes 2013: 1-18.
19. Zhang Q, Zhu L, Zheng M et al. Changes of serum omentin-1 levels in normal subjects, type 2 diabetes with overweight and obesity in Chinese adults. Ann Endocrinol (Paris) 2014; 75: 171-175.
20. Oswiecimska J, Suwała A, Swietochowska E et al. Serum omentin levels in adolescent girls with anorexia nervosa and obesity. Physiol Res 2015: 1-18
21. Hotta M, Shibasaki T, Sato K et al. The importance of body weight history in the occurrence and recovery of osteoporosis in patients with anorexia nervosa: evaluation by dual X-ray absorptiometry and bone metabolic markers. Eur J Endocrinol 1998; 1398: 276-283.
22. Weinbrenner T, Zittermann A, Gouni-Berthold I et al. Body mass index and disease duration are predictors of disturbed bone turnover in anorexia nervosa. A case-control study. Eur J Clin Nutr 2003; 57: 1262-1267.
23. Munoz-Calvo M T, Barrios V, Garcia de Alvaro MT et al. Maintained malnutrition produces a progressive decrease in OPG/RANKL ratio and leptin levels in patients with anorexia nervosa. Scand J Clin Lab Invest 2007; 67: 387-393.
24. Kobayashi Y, Udagawa N, Takahashi N. Action of RANKL and OPG for osteoclastogenesis. Crit Rev Eukaryot Gene Expr 2009; 19: 61-72.
25. Ostrowska Z, Ziora K, Kos-Kudła B et al. Melatonin, the RANKL/RANK//OPG system, and bone metabolism in girls with anorexia nervosa. Endokrynol Pol 2010; 61: 117-123
26. Ostrowska Z, Ziora K, Oswiecimska J et al. RANKL/RANK/OPG system and bone status in females with anorexia nervosa. Bone 2012; 50: 156-160
27. Ostrowska Z, Ziora K, Oswiecimska J et al. Dehydroepiandrosterone sulfate, osteoprotegerin and its soluble ligand sRANKL and bone metabolism in girls with anorexia nervosa. Postepy Hig Med Dosw (Online) 2012; 66: 655-662.
28. Ostrowska Z, Ziora K, Oswiecimska J et al. Assessment of the relationship between melatonin, hormones of the pituitary-ovarian,-thyroid and-adrenocortical axes, and osteoprotegerin and its ligand sRANKL in girls with anorexia nervosa. Postepy Hig Med Dosw (Online) 2013; 67: 433-441.
29. Ostrowska Z, Ziora K, Oswiecimska J et al. Bone metabolism, osteo-protegerin, receptor activator of nuclear factor-kB ligand and selected adipose tissue hormones in girls with anorexia nervosa. Endokrynol Pol 2014; 65: 33-39.
30. Lewitt A. Brzeczek K, Krupiewicz A. Interwencja zywieniowa w leczeniu anoreksji-wskazówki dietetyczne. Endokrynol Otył Zab Przem Mat 2008; 4: 128-136.
31. Wu SS, Liang OH, Liu Y et al. Omentin-1 stimulates human osteoblast proliferation through PI3K/Akt signal pathway. Int J Endocrinol 2013; 2013: 368970; doi: 10.1155/2013/368970.
32. Ostrowska Z. Menopause, obesity, and bone status. Postepy Hig Med Dosw (Online) 2009; 63: 39-46.
33. Misra M, Klibansky A. Anorexia nervosa and osteoporosis. Rev Endocr Metab Disord 2006; 7: 91-99.
34. Misra M, Miller KK, Cord J et al. Relationship between serum adipokines, insulin levels, and bone density in girls with anorexia nervosa. J Clin Endocrinol Metab 2007; 92: 1655-1661.
35. Misra M, Klibanski A. The neuroendocrine basis of anorexia nervosa and its impact on bone metabolism. Neuroendocrinology 2011; 93: 65-73.
36. Solmi M, Veronese N, Favaro A et al. Infammatory cytokines and anorexia nervosa: A meta-analysis of cross-sectional and longitudinal studies. Psychoneuroendocrinology 2015; 51: 237-252.
37. Ostrowska Z, Ziora K, Oswiecimska J et al. Selected pro-infamatory cytokines, bone metabolism, osteoprotegerin, and receptor activator of nuclear factor-kB ligand in girls with anorexia nervosa. Endokrynol Pol 2015; 66: 313-321.
38. Misra M, Soyka LA, Miller KK et al. Serum osteoprotegerin in adolescent girls with anorexia nervosa. J Clin Endocrinol Metab 2003; 88: 3916-3822.